Drug Profile

EOS 789

Alternative Names: AP-306 ; EOS-789

Latest Information Update: 30 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chugai Pharmaceutical
Developer Chugai Pharmaceutical; Shanghai Alebund Pharmaceuticals
Class Cardiovascular therapies; Small molecules
Mechanism of Action Phosphate transport protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Hyperphosphataemia

Most Recent Events

17 Mar 2026 EOS789 licensed to R1 Therapeutics worldwide excluding Greater China
17 Mar 2026 R1 Therapeutics and Alebund Pharmaceuticals plans a global phase-IIb trial for Hyperphosphataemia in 2026 , (NCT06712654)
08 Dec 2025 Phase-II clinical trials in Hyperphosphataemia in USA (PO) prior to December 2025 (Shanghai Alebund Pharmaceuticals, December 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com